お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
969069

非増殖性糖尿病性網膜症(NPDR):世界の臨床試験レビュー、2020年下半期

Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global Clinical Trials Review, H2 2020

出版日: | 発行: GlobalData | ページ情報: 英文 94 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
非増殖性糖尿病性網膜症(NPDR):世界の臨床試験レビュー、2020年下半期
出版日: 2020年10月29日
発行: GlobalData
ページ情報: 英文 94 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、2020年下半期に世界各地で行われている非増殖性糖尿病性網膜症(NPDR)治療薬の臨床試験について調査したもので、国(G7とE7)、地域、フェーズ、ステータス、エンドポイントのステータス、治験依頼者などの情報を提供しています。

調査範囲

  • 世界各地で行われている臨床試験の概況
  • 国(G7およびE7)、地域、ステータス、フェーズ、治験依頼者のタイプ、エンドポイントのステータスなど、臨床試験に関連する重要なデータ
  • 主要企業のレビューとその企業に関連するすべての臨床試験の情報(タイトル、フェーズ、ステータス)
  • 完了していない臨床試験(終了、中断、中止)とその理由
  • 過去5年間の被験者登録の動向
  • 過去3ヶ月間のニュース

目次

図表リスト

  • レポートのガイダンス
  • 調査範囲
  • 地域別の臨床試験
  • 国別の臨床試験と平均被験者登録数
  • アジア太平洋の臨床試験実施件数上位5ヶ国
  • 欧州の臨床試験実施件数上位5ヶ国
  • 北米の臨床試験実施件数上位国
  • 中東・アフリカの臨床試験実施件数上位5ヶ国
  • 中南米の臨床試験実施件数上位国
  • G7諸国での臨床試験:代謝障害治療薬の臨床試験のなかでNPDR治療薬が占める割合
  • G7諸国でのフェーズ別の臨床試験
  • G7諸国でのステータス別の臨床試験
  • E7諸国での臨床試験:代謝障害治療薬の臨床試験のなかでNPDR治療薬が占める割合
  • E7諸国でのフェーズ別の臨床試験
  • E7諸国でのステータス別の臨床試験
  • フェーズ別の臨床試験
  • フェーズ別の進行中の臨床試験
  • ステータス別の臨床試験
  • エンドポイントステータス別の臨床試験
  • 一定期間中に募集された被験者
  • 治験依頼者タイプ別の臨床試験
  • 著名な治験依頼者
  • 臨床試験に参加している主な企業
  • 著名な医薬品
  • 臨床試験プロファイルのスナップショット

付録

  • 略語
  • 定義
  • 調査手法
  • 2次調査
  • GlobalDataについて
  • お問い合わせ
  • 資料
図表

List of Tables

List of Tables

List of Tables

  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures

List of Figures

  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology
目次
Product Code: GDHC6468CTIDB

GlobalData's clinical trial report, "Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.